Actuate Therapeutics (NASDAQ:ACTU) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.

ACTU has been the subject of several other research reports. Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Actuate Therapeutics presently has a consensus rating of “Hold” and an average price target of $17.50.

Actuate Therapeutics Stock Performance

Shares of ACTU stock opened at $2.78 on Wednesday. Actuate Therapeutics has a 1 year low of $1.58 and a 1 year high of $11.99. The firm has a market capitalization of $65.91 million, a PE ratio of -2.65 and a beta of 0.85. The stock has a fifty day moving average of $2.87 and a two-hundred day moving average of $5.15.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.06. Equities research analysts predict that Actuate Therapeutics will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Actuate Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. ABS Direct Equity Fund LLC acquired a new position in shares of Actuate Therapeutics in the 4th quarter worth $40,000. Deutsche Bank AG lifted its holdings in shares of Actuate Therapeutics by 640.0% during the fourth quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock valued at $57,000 after purchasing an additional 8,051 shares during the last quarter. Barclays PLC lifted its holdings in shares of Actuate Therapeutics by 68.6% during the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after purchasing an additional 6,081 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Actuate Therapeutics in the 4th quarter valued at $102,000.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.